Skip to main content

Table 1 Patient, disease, and transplant characteristics

From: Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT

 

Type of transplant

 

Variable

Auto-HSCT

10/10 UD-HSCT

9/10 UD-HSCT

p

Number (total: 2879)

1202

1302

375

 

Gender, n (%)

   

0.046

 Male

681 (57)

694 (53)

188 (50)

 

 Female

518 (43)

608 (47)

187 (50)

 

WBC at diagnosis (×109/l), median (range)

13.8 (0.3–820)

10 (0.3–900)

9.9 (0.2–790)

0.32

 Missing

592

308

99

 

Cytogenetic risk, n (%)

   

<10−4

 Good

392 (33)

137 (11)

26 (7)

 

 Intermediate

624 (51)

550 (42)

165 (44)

 

 Poor

186 (16)

615 (47)

184 (49)

 

Molecular aberrations, n (%)

    

 NPM1 mutation

   

0.001

 Absent

64 (34)

150 (49)

41 (53)

 

 Present

124 (66)

154 (51)

37 (47)

 

 Missing

438

280

96

 

 FLT3-ITD

   

<10−4

 Absent

159 (70)

178 (48)

48 (44)

 

 Present

68 (30)

197 (52)

61 (56)

 

 Missing

399

209

66

 

 CEBPA mutation

   

0.07

 Absent

40 (82)

109 (90)

33 (97)

 

 Present

9 (18)

12 (10)

1 (3)

 

 Missing

577

463

140

 

No. of induction courses to reach CR1, n (%)

   

<10−4

 1

617 (51)

722 (56)

187 (50)

 

 More than 1

195 (17)

408 (31)

122 (33)

 

 Missing

390 (32)

172 (13)

66 (17)

 

MRD status at transplant

   

0.53

 MRD negative

361 (79)

352 (73)

81 (76)

 

 MRD positive

99 (21)

132 (27)

26 (24)

 

 Missing

742

818

268

 

Median age at transplant, years (range)

49 (18–78)

51 (18–76)

49 (18–69)

0.004

Median interval diagnosis transplant, days (range)

158 (75–813)

174 (66–997)

177 (83–766)

<10−4

Median interval CR1 transplant, days (range)

109 (21–365)

115 (18–447)

121 (21–348)

0.41

 Missing

390

172

66

 

Median year of transplant (range)

2008 (05–13)

2010 (05–13)

2010 (05–13)

<10−4

Stem cell source, n (%)

   

<10−4

 BM

53 (4)

258 (20)

58 (16)

 

 PBSCs

1149 (96)

1044 (80)

317 (84)

 

TBI-including conditioning, n (%)

   

<10−4

 No

1112 (93)

936 (72)

262 (70)

 

 Yes

85 (7)

364 (28)

113 (30)

 

Conditioning intensity, n (%)

    

 MAC

–

619 (48)

194 (52)

 

 RIC

–

677 (52)

180 (48)

 

Median follow-up, months (range)

45 (1–128)

36 (1–119)

25 (1–113)

 
  1. Legend: BM bone marrow, CEBPA CCAAT/enhancer-binding protein alpha, CR1 first complete remission, FLT3-ITD fms-like tyrosine kinase-internal tandem duplication, MAC myeloablative, MRD minimal residual disease, NPM1 nucleophosmin, PBSCs peripheral blood stem cells, RIC reduced-intensity, TBI total-body irradiation, WBC white blood cells